Adverse cutaneous drug reactions;Kutane legemiddelreaksjoner

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 18, 2005, Pages 2483-2487

  Lützow Holm, Claus ^a   Rønnevig, Jørgen Rikard ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; DRUG; ERYTHROMYCIN; ISONIAZID; MONOCLONAL ANTIBODY; NEUROLEPTIC AGENT; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHENAZONE; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM;

ADVERSE DRUG REACTION; CAUSALITY ASSESSMENT; DERMATITIS; DIFFERENTIAL DIAGNOSIS; DRUG FORMULARY; DRUG WITHDRAWAL; EPIDEMIOLOGY; ERYTHEMA MULTIFORME; HUMAN; INTENSIVE CARE; MEDLINE; NORWAY; PATHOGENESIS; PATIENT EDUCATION; PROGNOSIS; PUSTULOSIS; RASH; REVIEW; SKIN ALLERGY; SKIN DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNIVERSITY HOSPITAL; VIRUS INFECTION; BIBLIOGRAPHIC DATABASE; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FACTUAL DATABASE; INTERNET; PATHOLOGY; URTICARIA;

DATABASES, BIBLIOGRAPHIC; DATABASES, FACTUAL; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; EXANTHEMA; HUMANS; INTERNET; PATIENT EDUCATION; PROGNOSIS; URTICARIA;

EID: 26044438529     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003; 2: 278-99.
2. Revuz J, Valeyrie-Allanore L. Drug reactions. I: Bologna JL, Jorizzo JL, Rapini RP, red. Dermatology. Edinburgh: Mosby, 2003: 333-52.
3. Harg P, Madseji S. Legemiddelbivirkninger i Norge 2002. Årsrapport fra Statens Legemiddelverk. Oslo: Statens legemiddelverk, 2003.
4. Roujeau JC. Drug-induced skin reactions. I: Grob JJ, Stern RS, MacKie RM et al, red. Epidemiology, causes and prevention of skin diseases. London: Blackwell Science, 1997: 323-33.
5. Djien V, Bocquet H, Dupuy A et al. Symptomatology and markers of the severety of erytematous drug eruptions. Ann Dermatol Venereol 1999; 126: 247-50.
6. Bruinsma W. A guide to drug eruptions. Side effects in dermatology. 7. utg. Amsterdam: IMP, 2002.
7. Pichler W, Yawalkar N, Schmid S et al. Pathogenesis of drug-induced exanthems. Allergy 2002; 57: 884-93.
8. Naisbitt DJ. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnosic and predictive tests. Toxicology 2004; 194: 179-96.
9. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765-70.
10. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15: 1843-8.
11. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
12. Bigby M, Jick S, Jick H et al. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1995-1982. JAMA 1986; 256: 3358-63.
13. Aberer W, Romano A, Blanca M et al. Drug provocation testing in the diagnosis of drug hypersensitivy reactions: general considerations. Allergy 2003; 58: 854-63.
14. Hedner T, Samuelsson O, Lunde H. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992; 304: 941-6.
15. Wolkenstein P, Chosidow O, Flechet L et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234-6.
16. Roujeau JC, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med 1994; 331: 1272-85.
17. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal nercrolysis. N Engl J Med 1995; 333: 1600-7.
18. Stevens AM , Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child 1922; 24: 526-33.
19. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-61.
20. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003; 4: 561-72.
21. Viard I, Werhly P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blocade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
22. Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
23. Trent JT, Kirsner RS, Romanelli P et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 39: 39-43.
24. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6.
25. Austad J, Helsing P, Lützow-Holm C. Toksisk epidermal nekrolyse. http://www.legeforeningen.no/?id=35220(2.11.2004).